Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Novo Nordisk saw its stock drop 21% year-to-date, pressured by weaker-than-expected obesity drug trial results.

The FDA's new rule restricting the sale of compounded semaglutide could make it more difficult for some people to obtain ...

If you’re looking into weight loss drugs, liraglutide has no doubt popped up. It’s a diabetes and weight loss medication sold ...

Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled annual income and investment ...

The Weight Loss Drugs Market is poised for significant growth from 2025 to 2035. With increasing obesity rates, rising ...

Viking Therapeutics (NASDAQ: VKTX) is operating in one of the highest-growth pharma areas around. Viking doesn't sell weight ...

President Donald Trump is expected to announce sweeping tariffs on “all countries" affecting many industries, the likes of ...

The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk.

Eastern German gas company VNG, majority-owned by utility EnBW , said on Wednesday it will start test operations at a 30 ...

Hims & Hers not only recognizes these opportunities but has eagerly jumped on them. Earlier this year, during a shortage of such drugs, it took advantage of a legal loophole that allowed it to ...